| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,448 | 0,509 | 09.02. |
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Invitation to the Presentation of Cantargia's Annual Results for 2025 | LUND, SE / ACCESS Newswire / February 6, 2026 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA) will publish the company's annual results report for 2025 on Friday, February 20, 2026, at 07:00 a.m. CET.In... ► Artikel lesen | |
| 28.01. | Cantargia to Participate at Leerink Partners Global Healthcare Conference | LUND, SE / ACCESS Newswire / January 28, 2026 / Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA)(STO:CANTA) today announced that members of Cantargias management will participate in one-on-one... ► Artikel lesen | |
| 23.01. | Cantargia Reports First Patient Dosed in New US Investigator-Initiated Colorectal Cancer Study | LUND, SE / ACCESS Newswire / January 23, 2026 / Cantargia AB (Publ) (STO:CANTA) today reported that the first patient has been dosed in a Phase 1b/2 clinical trial investigating nadunolimab in combination... ► Artikel lesen | |
| 05.12.25 | Cantargia Provides Update on Overall Survival Data from TRIFOUR | LUND, SE / ACCESS Newswire / December 5, 2025 / Cantargia (STO:CANTA) - Cantargia AB (Publ) (NASDAQ:CANTA.ST) today announced an update on overall survival results from the Phase 1b/2 TRIFOUR study... ► Artikel lesen | |
| 19.11.25 | Cantargia Q3 2025: Erster Gewinn durch transformativen Otsuka-Deal |
